Cullinan Therapeutics Q2 net loss narrows
Cullinan Therapeutics Q2 net loss narrows
Overview
US biopharmaceutical firm's Q2 net loss narrowed yr/yr
Company ended Q2 with $356 mln in cash and investments, runway into 2029
Outlook
Cullinan expects cash runway into 2029 under current operating plan
Result Drivers
LOWER R&D SPENDING - Research and development expenses fell to $44.4 mln in Q2 from $61.0 mln a yr earlier
Company press release: ID:nGNX2MlcXv
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Loss |
| $53.70 mln |
|
Q2 Cash & Investments |
| $356 mln |
|
Q2 Operating Expenses |
| $57.25 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Cullinan Therapeutics, Inc. is $37.00, about 110.1% above its August 5 closing price of $17.61
Reuters Recommended Reads
Aug 4 - Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026
Aug 5 - Enliven Therapeutics Q2 net loss widens on higher expenses
Aug 5 - Immuneering expects cash runway to fund operations into 2029
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)